Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]

Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho Il Choi; Barry J. Hoffer; Chaim G. Pick; Nigel H. Greig; Dong Seok Kim

doi:10.1016/j.nbd.2024.106563

Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]

Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot Glotfelty, Lital Rachmany, Hee Kyung Kim, Ho Il Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig^*, Dong Seok Kim

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

The representative image for the “mTBI” group in panel B fig. 7 was accidentally duplicated from the picture for the “mTBI+ PT302 0.12 mg/kg” group in panel B fig. 6. The correct mTBI image appears in the revised panel B fig. 7 shown below. The correction does not impact the results or conclusions of this study. The authors would like to apologise for any inconvenience caused.[Formula

Original language	English
Article number	106563
Journal	Neurobiology of Disease
Volume	199
DOIs	https://doi.org/10.1016/j.nbd.2024.106563
State	Published - Sep 2024

Access to Document

10.1016/j.nbd.2024.106563

Fingerprint

Dive into the research topics of 'Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]'. Together they form a unique fingerprint.

Cite this

Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E., Rachmany, L., Kim, H. K., Choi, H. I., Hoffer, B. J., Pick, C. G., Greig, N. H., & Kim, D. S. (2024). Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]. Neurobiology of Disease, 199, Article 106563. https://doi.org/10.1016/j.nbd.2024.106563

@article{89024c28336a46948f828c58234880e0,

title = "Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]",

abstract = "The representative image for the “mTBI” group in panel B fig. 7 was accidentally duplicated from the picture for the “mTBI+ PT302 0.12 mg/kg” group in panel B fig. 6. The correct mTBI image appears in the revised panel B fig. 7 shown below. The correction does not impact the results or conclusions of this study. The authors would like to apologise for any inconvenience caused.[Formula",

author = "Miaad Bader and Yazhou Li and Daniela Lecca and Vardit Rubovitch and David Tweedie and Elliot Glotfelty and Lital Rachmany and Kim, {Hee Kyung} and Choi, {Ho Il} and Hoffer, {Barry J.} and Pick, {Chaim G.} and Greig, {Nigel H.} and Kim, {Dong Seok}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = sep,

doi = "10.1016/j.nbd.2024.106563",

language = "אנגלית",

volume = "199",

journal = "Neurobiology of Disease",

issn = "0969-9961",

publisher = "Academic Press Inc.",

}

Bader, M, Li, Y, Lecca, D, Rubovitch, V, Tweedie, D, Glotfelty, E, Rachmany, L, Kim, HK, Choi, HI, Hoffer, BJ, Pick, CG, Greig, NH & Kim, DS 2024, 'Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]', Neurobiology of Disease, vol. 199, 106563. https://doi.org/10.1016/j.nbd.2024.106563

Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]. / Bader, Miaad; Li, Yazhou; Lecca, Daniela et al.
In: Neurobiology of Disease, Vol. 199, 106563, 09.2024.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]

AU - Bader, Miaad

AU - Li, Yazhou

AU - Lecca, Daniela

AU - Rubovitch, Vardit

AU - Tweedie, David

AU - Glotfelty, Elliot

AU - Rachmany, Lital

AU - Kim, Hee Kyung

AU - Choi, Ho Il

AU - Hoffer, Barry J.

AU - Pick, Chaim G.

AU - Greig, Nigel H.

AU - Kim, Dong Seok

PY - 2024/9

Y1 - 2024/9

N2 - The representative image for the “mTBI” group in panel B fig. 7 was accidentally duplicated from the picture for the “mTBI+ PT302 0.12 mg/kg” group in panel B fig. 6. The correct mTBI image appears in the revised panel B fig. 7 shown below. The correction does not impact the results or conclusions of this study. The authors would like to apologise for any inconvenience caused.[Formula

AB - The representative image for the “mTBI” group in panel B fig. 7 was accidentally duplicated from the picture for the “mTBI+ PT302 0.12 mg/kg” group in panel B fig. 6. The correct mTBI image appears in the revised panel B fig. 7 shown below. The correction does not impact the results or conclusions of this study. The authors would like to apologise for any inconvenience caused.[Formula

UR - http://www.scopus.com/inward/record.url?scp=85196140849&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2024.106563

DO - 10.1016/j.nbd.2024.106563

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 38890024

AN - SCOPUS:85196140849

SN - 0969-9961

VL - 199

JO - Neurobiology of Disease

JF - Neurobiology of Disease

M1 - 106563

ER -

Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E et al. Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]. Neurobiology of Disease. 2024 Sep;199:106563. doi: 10.1016/j.nbd.2024.106563

Corrigendum to “Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury” [Neurobiology of Disease Volume 124 (2019) 439–453 /YNBDI_4338, (S0969996118306697), (10.1016/j.nbd.2018.11.023)]

Abstract

Access to Document

Other files and links

Fingerprint

Cite this